TriangleNCT04711135 · CITED IN SOURCE DOCUMENTS
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-02-12
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Absorbed Radiation Doses in Target Organ
Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration
Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up
Incidence of Adverse Events (AEs) During the Long Term Follow-up
Calculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold
Pharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data
Pharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data
Pharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Key Inclusion Criteria: 1. GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven, G1 or G2 (Ki-67 index =\< 20%), well differentiated GEP-NET. or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL. 2. Patients from 12 to \< 18 years of age at the time of enrollment. 3. Expression of somatostatin receptors confirmed by a somatostatin receptor imaging (SRI) modality within 3 months prior to enrollment, with tumor uptake observed in the target lesions more or equal to the normal liver uptake. 4. Performance status as determined by Karnofsky score \>= 50 or Lansky Play-Performance Scale score \>= 50. 5. Parent's ability to understand and the willingness to sign a written informed consent document for adolescents as determined by local regulations. Adolescents will sign assent along with parental/legal guardian consent or will co-sign consent with parent/legal guardian in accordance with local regulation, prior to participation in the study. Key Exclusion Criteria: 1. Laboratory parameters: 1. Estimated creatinine clearance calculated by the Cockroft-Gault method \< 70 mL/min 2. Hb concentration \<5.0 mmol/L (\<8.0 g/dL); WBC \<2x109/L; platelets \<75x109/L. 3. Total bilirubin \>3 x ULN for age. 4. Serum albumin \<3.0 g/dL unless prothrombin time is within the normal range. 2. Established or suspected pregnancy. 3. Breastfeeding female patients unless they accept to discontinue breastfeeding from the 1st dose until 3 months after the last administration of study drug. 4. Female patients of child-bearing potential, unless they are using highly effective methods of contraception during treatment and for 6 months after the last dose of Lutathera. 5. Sexually active male patients, unless they agree to remain abstinent or be willing to use effective methods of contraception. 6. Patients for whom in the opinion of the investigator other therapeutic options are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics. 7. Current spontaneous urinary incontinence. 8. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years. 9. Hypersensitivity to the study drug active substance or to any of the excipients. 10. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study. 11. Patient with known incompatibility to CT Scans with I.V. contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded. 12. Patients who received any investigational agent within the last 30 days.
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 12 Years
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
- intervention Names
- Drug: Lutetium [177Lu] oxodotreotide/dotatate
- label
- GEP-NET and PPGL
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- GEP-NET and PPGL
- description
- Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
- name
- Lutetium [177Lu] oxodotreotide/dotatate
- other Names
- Lutathera
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 11
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Absorbed radiation doses in target organ (e.g. kidney and bone marrow) was evaluated when all Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Pheochromocytoma and paraganglioma (PPGLs) as a pooled cohort patients had completed the 1st treatment of Lutathera and completed the dosimetry assessment.
- measure
- Absorbed Radiation Doses in Target Organ
- time Frame
- Up to 8 days after the first Lutetium [Lu 177] dotatate dose
- description
- Safety in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities after the first Lutathera dose.
- measure
- Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration
- time Frame
- during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)
- secondary Outcomes
- description
- Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.
- measure
- Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up
- time Frame
- From first Lutetium [Lu 177] dotatate dose to 6 months after last dose, approx. 12 months
- description
- Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.
- measure
- Incidence of Adverse Events (AEs) During the Long Term Follow-up
- time Frame
- Up to 5 years after the last Lutetium [Lu 177] dotatate dose
- description
- A comparative assessment of dosimetry for organs at risk specifically kidneys and bone marrow, was performed between adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study to confirm the probability of exceeding 29 Gy (kidneys) \& 2 Gy (bone marrow) thresholds.
- measure
- Calculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold
- time Frame
- After 4 cycles of 7.4 GBq/200 mCi; each cycle is 8+/-1 weeks
- description
- A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
- measure
- Pharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data
- time Frame
- Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
- description
- A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
- measure
- Pharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data
- time Frame
- Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
- description
- A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.
- measure
- Pharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data
- time Frame
- Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Full study description
- brief Summary
- This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
- detailed Description
- The study schedule for each patient consists of the screening period (up to 2 weeks) followed by the treatment period (4 treatment administrations at 8-week interval), and the follow-up period (10 years). The treatment period will consist of 4 Lutathera treatments administered at 8-week intervals. Lutathera administration will occur on Week 1 Day 1 of each cycle. Each patient will receive a total of 4 doses of Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi). An infusion of 2.5% Lysine - Arginine amino acid (AA) solution will be co-administered with each Lutathera dose for renal protection according to the approved Lutathera local prescribing information. An antiemetic will be administered prior to infusion of the AA solution for prevention of infusion-related nausea and vomiting. The dosimetry and PK assessments will be performed during the first week after the 1st Lutathera dose, i.e. one time during the study treatment period for each patient. The dosimetry analysis will allow for estimation from the 1st Lutathera administration of the cumulative absorbed radiation dose from 4 Lutathera doses and also for taking a decision on the next dose levels. In the exceptional circumstances when dosimetry cannot be performed in a particular patient after the first Lutathera dose, it should be completed as soon as feasible upon a later dose. In order to minimize risk for each study subject, an accelerated analysis of dosimetry and safety data will be performed for each patient in the study, to enable the Investigator to take a decision for the subsequent Lutathera doses. The results of dosimetry assessments (imaging and blood dosimetry) will be provided to the investigators for their evaluation prior to administration of subsequent therapeutic cycles in each patient. A total follow-up period of 10 years (120 months) after the last Lutathera dose will take place for each patient who received at least one dose of Lutathera. This follow-up period will be comprised of a short-term follow-up of 6 months to evaluate cumulative Lutathera toxicities, followed by a long-term follow up of another 114 months. An external Data and Safety Monitoring Board (DSMB) will also operate in the study to evaluate accumulating safety and dosimetry data, to ensure the safety of adolescents enrolled in the study, and to provide recommendations to investigators as well as to the clinical team in charge of conducting the study.
Source references
- references
- citation
- Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, Wan S, Ceraulo A, Kluczewska-Galka A, Gamez-Cenzano C, States LJ, El Khouli R, Aimone P, Perraud K, Kollar G, Khanshan F, Blumenstein L, Brouri F, Giraudet AL. Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):4001-4015. doi: 10.1007/s00259-025-07246-7. Epub 2025 Apr 8.
- pmid
- 40198358
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-27b41e1ac0cf8026ac68
- requested nct id
- NCT04711135
- primary nct id
- NCT04711135
- source kind
- fda_spl_label
- source record id
- 74d44dec-f079-43b7-94ac-989a948f53ec
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 16dab65006fcf513133863fee1ccb99f6f4a4e1e182e807136acf385c69315d9
- payload
- application numbers
- NDA208700
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-27b41e1ac0cf8026ac68
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04711135
- occurrences
- context exact
- ardial infarction (1%), and neuroendocrine hormonal crisis (1%). Pediatric Population NETTER-P Safety data are available from 9 pediatric patients in NETTER-P (NCT04711135), an international, multi-center, single-arm, open-label trial of patients with somatostatin receptor-positive tumors, including 4 patients with GEP-NETs. Pati
- end
- 7122
- exact text
- NCT04711135
- start
- 7111
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/55/adverse_reactions/0
- source kind
- fda_spl_label
- source record id
- 74d44dec-f079-43b7-94ac-989a948f53ec
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 8f49ae160162bf6ef749fce0c39a55e698d09b4461583ba600a4cc4c824a61f0
- spl effective time
- 20260115
- spl set id
- 72d1a024-00b7-418a-b36e-b2cb48f2ab55
Preserved source evidence · Not medical advice